New Two-Pronged cell therapy offers hope for Tough-to-Treat blood cancer

NCT ID NCT07359014

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

Summary

This study is testing a new type of personalized cell therapy called CD19/BCMA CAR-T for adults with multiple myeloma that has come back or stopped responding to standard treatments. Doctors will collect and modify a patient's own immune cells to attack the cancer, then infuse them back. The main goals are to see if the treatment is safe and how well it works to control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSE MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Xuzhao Zhang
RECRUITING

Hangzhou, 310003, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RELAPSE MULTIPLE MYELOMA